% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • yingand_yang yingand_yang Dec 15, 2009 9:50 AM Flag


    SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., Dec. 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTA® (exenatide) injection taken twice daily, in patients with type 2 diabetes. After 24 weeks of treatment, patients taking exenatide once weekly experienced a statistically superior reduction in A1C, a measure of average blood sugar over three months, of 1.6 percentage points from baseline, compared to a reduction of 0.9 percentage points for BYETTA. Patients treated with exenatide once weekly achieved a mean A1C of 7.1 percent compared with a mean A1C of 7.7 percent in those treated with BYETTA. Both treatment groups achieved statistically significant weight loss by the end of the study, with an average loss of 5.1 pounds for patients taking exenatide once weekly and 3.0 pounds for patients taking BYETTA.

    These findings are consistent with the results of other studies of exenatide once weekly and BYETTA. The companies conducted DURATION-5 to support regulatory submissions outside of the U.S. and provide additional controlled clinical data on the commercially manufactured product. DURATION is a series of clinical trials designed to test the superiority of exenatide once weekly as compared to currently available type 2 diabetes medications.

    "The DURATION-5 data reinforce the efficacy of BYETTA and potential of exenatide once weekly in improving blood glucose control as measured by A1C, and build upon other successful DURATION trials," said Orville G. Kolterman, M.D., senior vice president of research and development, Amylin Pharmaceuticals. "More importantly, these results continue to suggest that if approved, exenatide once weekly could play an important role in advancing the treatment of type 2 diabetes by providing patients the opportunity for improved A1C control and weight loss with just one dose per week."

    Approximately 80 percent of patients completed the study. Consistent with previous DURATION trials, the most frequently reported adverse event in both groups was nausea, reported less frequently by exenatide once weekly users (14 percent) than by BYETTA users (35 percent). There were no major hypoglycemic events. Cases of minor hypoglycemia in both groups were limited to patients using background sulfonylurea therapy.

    The 24-week, open-label superiority study included approximately 250 participants with type 2 diabetes who were not achieving adequate glucose control using background therapies that included diet and exercise, metformin, sulfonylurea, thiazolidinediones or a combination of the agents. Patients were randomized to receive either exenatide once weekly or BYETTA. Patients in the exenatide once weekly treatment arm received 2 milligrams once a week, while patients in the BYETTA arm received 5 micrograms twice a day for the first four weeks and 10 micrograms twice a day for the remaining 20 weeks. The primary endpoint was reduction in A1C; secondary endpoints included change in body weight and fasting plasma glucose, safety and tolerability.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • very simple answer... it can causes pancreatic failure, and the FDA told the doctors to be careful. long acting insuline just isn't meant to stay in the body too long. by the way, this for long acting, which doesn't do much w/ afresa... not yet .. but glp-1 is being developed by mnkd.

    • "The "longs and pumpers" want you to believe that the competition has already rolled over for Afresa."

      "Inhaling a milk jug and a half of powder every year can't be a good thing!!!"

      Just a thought!!!

    • Can the board enlighten me on why this new drug isn't going to take market share from MNKD? It's a once a week treatment, it lowers A1C's and enables weight loss.

      I'd really like to understand why this isn't a threat....

      • 3 Replies to opc11
      • It's just another long acting GLP-1 analog. Basically Byetta but with less injections.

        Just search this board for Byetta for more info. You can also google for "Byetta sucks" or "problems with Byetta" for example.

        One of the main problems is that GLP-1 is intended to be in the blood for a very short time, not all the time like with Byetta/exanetide/etc. This wears out the pancreas faster.

        Works fine for a few years, until it doesn't but then your diabetes is a lot worse then before you started treatment.

        I'm sure it will capture a percentage of the market though. Unless more safety issues emerge.

      • Have to say I'm completely surprised by the lack of response. Perhaps this is one of those situations where we should all just put our heads in the sand and hope the competitor's drug goes away......

        Very interesting.

    • Great! Compare a drug to another that may cause kidney failure. A big move for science.

    • Amylin, Lilly and Alkermes submitted a new drug application (NDA) for exenatide once weekly to the U.S. Food and Drug Administration (FDA) in May 2009; the NDA was accepted for review in July 2009. Lilly will be responsible for marketing exenatide once weekly outside the U.S. and expects to submit a marketing application to the European Medicines Agency by the end of the second quarter in 2010.

      Diabffects more than 24 million people in the U.S., and it is estimated that by 2010, it will affect 284.6 million adults worldwide.(i, ii) Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the U.S. and costs approximately $174 billion per year in direct and indirect medical expenses.(iii)

      According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(v) Data indicate that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(vi, vii)

      About BYETTA® (exenatide) injection

      BYETTA is the first and only FDA-approved GLP-1 receptor agonist for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain.

      BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes mellitus, when used with a diet and exercise program. BYETTA is not insulin and should not be taken instead of insulin. BYETTA is not recommended to be taken with insulin. BYETTA is not for people with type 1 diabetes or people with diabetic ketoacidosis.

      BYETTA provides sustained A1C control and low incidence of hypoglycemia when used alone or in combination with metformin or a thiazolidinedione, with potential weight loss. BYETTA is not a weight loss product. BYETTA was approved in April 2005 and has been used by more than one million patients since its introduction. For full prescribing information, visit

4.525-0.105(-2.27%)12:51 PMEDT